Published in Nat Mater on April 17, 2011
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev (2012) 3.34
Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics (2012) 2.35
Processing pathway dependence of amorphous silica nanoparticle toxicity: colloidal vs pyrolytic. J Am Chem Soc (2012) 1.86
Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol (2012) 1.85
Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Sci Transl Med (2014) 1.73
Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility. Acc Chem Res (2013) 1.68
A nanoparticle formulation that selectively transfects metastatic tumors in mice. Proc Natl Acad Sci U S A (2013) 1.55
Mesoporous silica-supported lipid bilayers (protocells) for DNA cargo delivery to the spinal cord. J Control Release (2013) 1.43
Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat Mater (2012) 1.40
Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nanoscale (2011) 1.25
Biomimetic delivery with micro- and nanoparticles. Adv Mater (2012) 1.25
Hybrid nanoparticles for detection and treatment of cancer. Adv Mater (2012) 1.16
Bioresponsive mesoporous silica nanoparticles for triggered drug release. J Am Chem Soc (2011) 1.15
Investigating the optimal size of anticancer nanomedicine. Proc Natl Acad Sci U S A (2014) 1.13
Silica-based nanoprobes for biomedical imaging and theranostic applications. Chem Soc Rev (2012) 1.13
Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy. ACS Nano (2015) 1.13
The role of philosophy of science in Responsible Research and Innovation (RRI): the case of nanomedicine. Life Sci Soc Policy (2014) 1.12
Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy. Nat Commun (2014) 1.11
Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects. Nano Today (2014) 1.09
Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci Rep (2013) 1.09
Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers. ACS Nano (2012) 1.08
Biomimetic surface engineering of lanthanide-doped upconversion nanoparticles as versatile bioprobes. Angew Chem Int Ed Engl (2012) 1.07
Drug delivery: One nanoparticle, one kill. Nat Mater (2011) 1.06
Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One (2012) 1.06
Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PLoS One (2011) 1.05
Polysilsesquioxane nanoparticles for targeted platin-based cancer chemotherapy by triggered release. Angew Chem Int Ed Engl (2011) 1.04
Remotely activated protein-producing nanoparticles. Nano Lett (2012) 1.01
Nanoparticles for combination drug therapy. ACS Nano (2013) 0.99
Nanoparticle-programmed self-destructive neural stem cells for glioblastoma targeting and therapy. Small (2013) 0.97
Lipid-Coated Nanoscale Coordination Polymers for Targeted Delivery of Antifolates to Cancer Cells. Chem Sci (2012) 0.96
Lipid nanotechnology. Int J Mol Sci (2013) 0.96
Mesoporous Silica Nanoparticles with Co-Condensed Gadolinium Chelates for Multimodal Imaging. Nanomaterials (Basel) (2012) 0.95
Nanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer. Adv Funct Mater (2014) 0.95
Mechanistic modeling identifies drug-uptake history as predictor of tumor drug resistance and nano-carrier-mediated response. ACS Nano (2013) 0.95
Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer. ACS Nano (2016) 0.95
Diamond-lipid hybrids enhance chemotherapeutic tolerance and mediate tumor regression. Adv Mater (2013) 0.94
Multifunctional hybrid silica nanoparticles for controlled doxorubicin loading and release with thermal and pH dually response. J Mater Chem B Mater Biol Med (2012) 0.93
Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. ACS Nano (2015) 0.93
Blood-stable, tumor-adaptable disulfide bonded mPEG-(Cys)4-PDLLA micelles for chemotherapy. Biomaterials (2012) 0.93
Student award winner in the Ph.D. category for the 2013 society for biomaterials annual meeting and exposition, april 10-13, 2013, Boston, Massachusetts : biomaterial-mediated cancer-specific DNA delivery to liver cell cultures using synthetic poly(beta-amino ester)s. J Biomed Mater Res A (2013) 0.92
Photoluminescent carbon nanotags from harmful cyanobacteria for drug delivery and imaging in cancer cells. Sci Rep (2014) 0.89
Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells. Trends Biotechnol (2014) 0.88
Selecting improved peptidyl motifs for cytosolic delivery of disparate protein and nanoparticle materials. ACS Nano (2013) 0.88
Targeted drug delivery systems mediated by a novel Peptide in breast cancer therapy and imaging. PLoS One (2013) 0.88
Nanoengineering approaches to the design of artificial antigen-presenting cells. Nanomedicine (Lond) (2013) 0.88
Photoexpulsion of surface-grafted ruthenium complexes and subsequent release of cytotoxic cargos to cancer cells from mesoporous silica nanoparticles. J Am Chem Soc (2013) 0.88
Iron oxide nanoparticle-based magnetic resonance method to monitor release kinetics from polymeric particles with high resolution. Anal Chem (2012) 0.88
Nanofountain probe electroporation (NFP-E) of single cells. Nano Lett (2013) 0.87
Size-selective pH-operated megagates on mesoporous silica materials. Nanoscale (2012) 0.87
Glycosphingolipid-functionalized nanoparticles recapitulate CD169-dependent HIV-1 uptake and trafficking in dendritic cells. Nat Commun (2014) 0.87
Potential therapeutic approaches for modulating expression and accumulation of defective lamin A in laminopathies and age-related diseases. J Mol Med (Berl) (2012) 0.87
Involvement of lysosomal exocytosis in the excretion of mesoporous silica nanoparticles and enhancement of the drug delivery effect by exocytosis inhibition. Small (2012) 0.87
Coercing bisphosphonates to kill cancer cells with nanoscale coordination polymers. Chem Commun (Camb) (2012) 0.87
The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. Nanomedicine (Lond) (2015) 0.86
Nanostructured porous Si-based nanoparticles for targeted drug delivery. Biomatter (2013) 0.86
Delivering hydrophilic and hydrophobic chemotherapeutics simultaneously by magnetic mesoporous silica nanoparticles to inhibit cancer cells. Int J Nanomedicine (2012) 0.86
Fluorescent nanodiamonds embedded in biocompatible translucent shells. Small (2014) 0.85
Multivalent porous silicon nanoparticles enhance the immune activation potency of agonistic CD40 antibody. Adv Mater (2012) 0.85
Effect of magnetic nanoparticles on apoptosis and cell cycle induced by wogonin in Raji cells. Int J Nanomedicine (2012) 0.85
Biomimetic particles as therapeutics. Trends Biotechnol (2015) 0.85
Trojan-horse nanotube on-command intracellular drug delivery. Nano Lett (2012) 0.85
Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy. Adv Drug Deliv Rev (2015) 0.84
ATP-responsive DNA-graphene hybrid nanoaggregates for anticancer drug delivery. Biomaterials (2015) 0.84
Functioning of nanovalves on polymer coated mesoporous silica Nanoparticles. Nanoscale (2013) 0.83
Multifunctional nanocapsules for simultaneous encapsulation of hydrophilic and hydrophobic compounds and on-demand release. ACS Nano (2012) 0.83
Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles. Int J Nanomedicine (2012) 0.83
Multifunctional to multistage delivery systems: The evolution of nanoparticles for biomedical applications. Chin Sci Bull (2012) 0.83
Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy. Ther Deliv (2012) 0.83
High-density arrays of submicron spherical supported lipid bilayers. Anal Chem (2012) 0.82
Continuing progress toward controlled intracellular delivery of semiconductor quantum dots. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2014) 0.82
Synergistic effect of pH-responsive folate-functionalized poloxamer 407-TPGS-mixed micelles on targeted delivery of anticancer drugs. Int J Nanomedicine (2015) 0.81
Nanoparticle ligand presentation for targeting solid tumors. AAPS PharmSciTech (2014) 0.80
Delivery of ricin toxin a-chain by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers. Adv Healthc Mater (2012) 0.80
Assembly of bio-nanoparticles for double controlled drug release. PLoS One (2013) 0.80
Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Rev (2015) 0.80
Fabrication of multiresponsive bioactive nanocapsules through orthogonal self-assembly. Angew Chem Int Ed Engl (2014) 0.80
Nanoparticle immunotherapy: Combo combat. Nat Mater (2012) 0.79
Label-free luminescent mesoporous silica nanoparticles for imaging and drug delivery. Theranostics (2013) 0.79
Study of the efficacy of antimalarial drugs delivered inside targeted immunoliposomal nanovectors. Nanoscale Res Lett (2011) 0.79
Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma. World J Gastroenterol (2015) 0.79
pH-Sensitive stimulus-responsive nanocarriers for targeted delivery of therapeutic agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.78
Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release. Proc Natl Acad Sci U S A (2016) 0.78
Nanomedicine in chemoradiation. Ther Deliv (2013) 0.78
Lipid-Mediated Targeting with Membrane-Wrapped Nanoparticles in the Presence of Corona Formation. ACS Nano (2016) 0.78
Exploring the tumor microenvironment with nanoparticles. Cancer Treat Res (2015) 0.77
Luminescent silica nanoparticles for cancer diagnosis. Curr Med Chem (2013) 0.77
Ligand-targeted theranostic nanomedicines against cancer. J Control Release (2016) 0.77
The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity. Clin Exp Immunol (2015) 0.77
Dressing up Nanoparticles: A Membrane Wrap to Induce Formation of the Virological Synapse. ACS Nano (2015) 0.77
Development of individualized anti-metastasis strategies by engineering nanomedicines. Chem Soc Rev (2015) 0.77
Yoctowells as a simple model system for the encapsulation and controlled release of bioactive molecules. Sci Rep (2013) 0.76
Protocells: Modular Mesoporous Silica Nanoparticle-Supported Lipid Bilayers for Drug Delivery. Small (2016) 0.76
Nanoporous silica-based protocells at multiple scales for designs of life and nanomedicine. Life (Basel) (2015) 0.76
Supramolecular nanosubstrate-mediated delivery for reprogramming and transdifferentiation of mammalian cells. Small (2015) 0.76
Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications. J Vis Exp (2015) 0.76
Validation of a Janus role of methotrexate-based PEGylated chitosan nanoparticles in vitro. Nanoscale Res Lett (2014) 0.76
A Fluorescent Tile DNA Diagnocode System for In Situ Rapid and Selective Diagnosis of Cytosolic RNA Cancer Markers. Sci Rep (2015) 0.76
Functional peptides for siRNA delivery. Adv Drug Deliv Rev (2016) 0.75
Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cells. Proc Natl Acad Sci U S A (2016) 0.75
pH-Sensitive Pt Nanocluster Assembly Overcomes Cisplatin Resistance and Heterogeneous Stemness of Hepatocellular Carcinoma. ACS Cent Sci (2016) 0.75
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 15.83
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release (2000) 14.89
Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer (2005) 13.49
Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov (2008) 12.72
Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater (2009) 11.95
Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov (2005) 10.97
Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol (2008) 8.23
Comparison of the mechanism of toxicity of zinc oxide and cerium oxide nanoparticles based on dissolution and oxidative stress properties. ACS Nano (2008) 5.68
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol (2001) 4.45
Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev (1999) 4.02
The conformation of membranes. Nature (1991) 3.96
Immunotoxin therapy of cancer. Nat Rev Cancer (2006) 3.93
Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano (2008) 3.88
The emerging nanomedicine landscape. Nat Biotechnol (2006) 3.60
Mesoporous materials for drug delivery. Angew Chem Int Ed Engl (2007) 2.93
A mesoporous silica nanosphere-based carrier system with chemically removable CdS nanoparticle caps for stimuli-responsive controlled release of neurotransmitters and drug molecules. J Am Chem Soc (2003) 2.69
Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci U S A (2007) 2.27
Stimuli-responsive controlled-release delivery system based on mesoporous silica nanorods capped with magnetic nanoparticles. Angew Chem Int Ed Engl (2005) 2.02
High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J Biol Chem (2005) 1.67
Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res (2000) 1.59
Nanogeometry: beyond drug delivery. Nat Nanotechnol (2008) 1.54
A reversible molecular valve. Proc Natl Acad Sci U S A (2005) 1.49
Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim Biophys Acta (2006) 1.48
Porous nanoparticle supported lipid bilayers (protocells) as delivery vehicles. J Am Chem Soc (2009) 1.47
Nuclear targeting peptide scaffolds for lipofection of nondividing mammalian cells. Nat Biotechnol (1999) 1.39
Enzyme-responsive snap-top covered silica nanocontainers. J Am Chem Soc (2008) 1.38
Statistical pattern matching facilitates the design of polyvalent inhibitors of anthrax and cholera toxins. Nat Biotechnol (2006) 1.32
Electrostatically mediated liposome fusion and lipid exchange with a nanoparticle-supported bilayer for control of surface charge, drug containment, and delivery. J Am Chem Soc (2009) 1.23
Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol Cancer Ther (2008) 1.16
Structure and fluctuations of a single floating lipid bilayer. Proc Natl Acad Sci U S A (2005) 1.12
Membrane permeabilization and efficient gene transfer by a peptide containing several histidines. Bioconjug Chem (1998) 1.10
DNA translocation through an array of kinked nanopores. Nat Mater (2010) 1.03
Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann Oncol (2009) 0.99
Microparticles with bimodal nanoporosity derived by microemulsion templating. Langmuir (2009) 0.97
Formation, stability, and mobility of one-dimensional lipid bilayers on polysilicon nanowires. Nano Lett (2007) 0.95
Neutron reflectivity study of lipid membranes assembled on ordered nanocomposite and nanoporous silica thin films. Langmuir (2005) 0.95
Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance. Biochim Biophys Acta (2001) 0.91
Supported membranes on chemically structured and rough surfaces. Phys Rev E Stat Nonlin Soft Matter Phys (2001) 0.90
Silica nanoparticle supported lipid bilayers for gene delivery. Chem Commun (Camb) (2009) 0.89
Tension-induced morphological transition in mixed lipid bilayers. Langmuir (2006) 0.86
Supported bilayers: combined specular and diffuse X-ray scattering. Eur Phys J E Soft Matter (2010) 0.84
Drug delivery in acute myeloid leukemia. Expert Opin Drug Deliv (2008) 0.82
Characterization of 5-fluorouracil loaded liposomes prepared by reverse-phase evaporation or freezing-thawing extrusion methods: study of drug release. Biochim Biophys Acta (1993) 0.82
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67
The Protein Data Bank. Acta Crystallogr D Biol Crystallogr (2002) 14.44
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
Age and acute myeloid leukemia. Blood (2006) 6.46
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 4.98
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35
Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A (2006) 3.70
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2011) 3.40
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA (2009) 2.72
Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. J Clin Oncol (2008) 2.51
A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med (2006) 2.36
Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood (2005) 2.22
Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood (2012) 2.09
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood (2010) 2.05
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood (2012) 1.90
Processing pathway dependence of amorphous silica nanoparticle toxicity: colloidal vs pyrolytic. J Am Chem Soc (2012) 1.86
Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst (2013) 1.81
BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat Med (2013) 1.79
Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood (2008) 1.79
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood (2012) 1.78
Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood (2006) 1.74
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood (2011) 1.74
Metnase mediates chromosome decatenation in acute leukemia cells. Blood (2009) 1.74
Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility. Acc Chem Res (2013) 1.68
An inorganic-organic proton exchange membrane for fuel cells with a controlled nanoscale pore structure. Nat Nanotechnol (2010) 1.67
Viral nanoparticles donning a paramagnetic coat: conjugation of MRI contrast agents to the MS2 capsid. Nano Lett (2006) 1.67
Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood (2012) 1.66
Dissecting metal ion-dependent folding and catalysis of a single DNAzyme. Nat Chem Biol (2007) 1.63
Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood (2002) 1.62
Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood (2012) 1.61
Confinement-induced quorum sensing of individual Staphylococcus aureus bacteria. Nat Chem Biol (2009) 1.61
In vivo lipidomics using single-cell Raman spectroscopy. Proc Natl Acad Sci U S A (2011) 1.53
A modular microfluidic architecture for integrated biochemical analysis. Proc Natl Acad Sci U S A (2005) 1.52
Porous nanoparticle supported lipid bilayers (protocells) as delivery vehicles. J Am Chem Soc (2009) 1.47
Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. Blood (2012) 1.47
Self-assembly of ordered, robust, three-dimensional gold nanocrystal/silica arrays. Science (2004) 1.47
Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood (2006) 1.46
Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia. Blood (2007) 1.46
Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet (2013) 1.45
A new human natural killer leukemia cell line, IMC-1. A complex chromosomal rearrangement defined by spectral karyotyping: functional and cytogenetic characterization. Leuk Res (2004) 1.43
Mesoporous silica-supported lipid bilayers (protocells) for DNA cargo delivery to the spinal cord. J Control Release (2013) 1.43
Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood (2004) 1.41
ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol (2012) 1.39
[Surgery and blood transfusion in Jehovah's witnesses: a medical-legal review]. Cir Esp (2007) 1.39
Remotely powered self-propelling particles and micropumps based on miniature diodes. Nat Mater (2007) 1.38
Sub-10 nm thick microporous membranes made by plasma-defined atomic layer deposition of a bridged silsesquioxane precursor. J Am Chem Soc (2007) 1.35
Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine (2010) 1.33
Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906. Pediatr Blood Cancer (2011) 1.33
Aerosol-assisted self-assembly of single-crystal core/nanoporous shell particles as model controlled release capsules. J Am Chem Soc (2006) 1.32
Modulus-density scaling behaviour and framework architecture of nanoporous self-assembled silicas. Nat Mater (2007) 1.28
Highly sensitive and selective colorimetric sensors for uranyl (UO2(2+)): development and comparison of labeled and label-free DNAzyme-gold nanoparticle systems. J Am Chem Soc (2008) 1.28
Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2. J Mol Biol (2008) 1.28
A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS One (2011) 1.28
Long-range interlayer alignment of intralayer domains in stacked lipid bilayers. Nat Mater (2012) 1.27
Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3. Mol Cell Biol (2004) 1.26
Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study. Blood (2011) 1.25
Cell-directed assembly of lipid-silica nanostructures providing extended cell viability. Science (2006) 1.24
Integrating sensing hydrogel microstructures into micropatterned hepatocellular cocultures. Langmuir (2009) 1.24
Characterization of a Cdc42 protein inhibitor and its use as a molecular probe. J Biol Chem (2013) 1.24
Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation. Br J Haematol (2008) 1.24
Heat shock protein 70 regulates cellular redox status by modulating glutathione-related enzyme activities. Cell Stress Chaperones (2007) 1.23
Electrostatically mediated liposome fusion and lipid exchange with a nanoparticle-supported bilayer for control of surface charge, drug containment, and delivery. J Am Chem Soc (2009) 1.23
Direct photochemical patterning and refunctionalization of supported phospholipid bilayers. J Am Chem Soc (2004) 1.22
Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. Blood (2008) 1.20
RNA recognition site of PP7 coat protein. Nucleic Acids Res (2002) 1.19
Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses. Vaccine (2006) 1.19
Lipid lateral mobility and membrane phase structure modulation by protein binding. J Am Chem Soc (2006) 1.19
Instantaneous and quantitative functionalization of gold nanoparticles with thiolated DNA using a pH-assisted and surfactant-free route. J Am Chem Soc (2012) 1.17
Functional DNA nanotechnology: emerging applications of DNAzymes and aptamers. Curr Opin Biotechnol (2006) 1.15
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. Br J Haematol (2009) 1.13
Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group. J Clin Oncol (2010) 1.13
Pediatric acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program (2003) 1.13
Phospholipid morphologies on photochemically patterned silane monolayers. J Am Chem Soc (2005) 1.12
Surface interactions with compartmentalized cellular phosphates explain rare earth oxide nanoparticle hazard and provide opportunities for safer design. ACS Nano (2014) 1.12